Dariohealth Corp Stock Price, News & Analysis

DarioHealth Corp. (Nasdaq: DRIO) will participate in the Cowen 42nd Annual Healthcare Conference virtually from March 7-9, 2022. CEO Erez Raphael and President Rick Anderson will hold a fireside chat on March 8 from 11:10-11:40 AM ET. A live webcast will be available here and on their Investor Relations website, with a replay accessible for 90 days. DarioHealth specializes in digital therapeutics, providing solutions for chronic conditions and promoting health improvements through AI-driven, personalized platforms.

DarioHealth Corp. (Nasdaq: DRIO) has announced a strategic agreement with Sanofi U.S., valued at $30 million. This multi-year contract aims to enhance the commercial adoption of Dario's digital therapeutics and expand digital health solutions on its platform. The collaboration will significantly increase Dario's market reach in health plans and employers. Dario will leverage its comprehensive digital therapeutics to help manage chronic conditions, aligning with Sanofi’s goal to integrate healthcare and technology for chronic disease management.

DarioHealth Corp. (Nasdaq: DRIO) announced a registered direct offering on February 28, 2022, with institutional investors, raising approximately $40 million. The sale includes about 5.34 million shares priced at $7.49 each, along with pre-funded warrants. The proceeds will support the expansion of its digital health platform in the U.S. market and further development of new solutions. The offering is expected to close by March 3, 2022. It is conducted under a shelf registration statement with the SEC, ensuring compliance with securities laws.

DarioHealth Corp. (Nasdaq: DRIO) announced a study published in the Journal of Medical Internet Research highlighting the effectiveness of its integrated digital therapeutics platform in managing both diabetes and hypertension. The study revealed that users managing both conditions saw a significant reduction in average blood glucose and blood pressure levels, with 27% achieving more than a 10mmHg systolic blood pressure reduction. Dario emphasizes the importance of a holistic approach to chronic condition management and aims to lead in integrated health solutions.

DarioHealth Corp. (Nasdaq: DRIO) announced an agreement to acquire assets from Physimax Technologies Ltd., specializing in computer vision technology for musculoskeletal screening. This technology, used by organizations like the NBA and U.S. military, offers automated injury assessments and personalized training programs. The acquisition involves issuing up to 256,660 shares and a cash payment of $500,000, alongside assuming liabilities of approximately $1,020,000. DarioHealth aims to enhance its offerings, promoting growth in musculoskeletal health care while reducing reliance on human support.

DarioHealth Corp. (NASDAQ-CM: DRIO) announced a contract with a large regional health plan to provide its digital therapeutic solution for diabetes to eligible Medicaid members in the mid-Atlantic region. Expected to contribute to revenue in Q2 2022, this partnership aims to improve access to innovative diabetes care and reduce medical costs for Medicaid participants, who face significantly higher healthcare expenses. DarioHealth’s digital therapeutics platform addresses various chronic conditions, emphasizing personalized experiences and behavior change for better health outcomes.

DarioHealth Corp. (Nasdaq: DRIO) is set to host an investor webinar on January 19, 2022, at 8 am ET, focusing on emerging digital health trends. The event will feature insights from industry experts Sari Kaganoff and David Kaplan, along with DarioHealth executives detailing the company's digital therapeutics platform and 2021 achievements. DarioHealth aims to transform healthcare with its AI-powered platform addressing chronic conditions like diabetes and hypertension. To register, visit their website.